Active, not recruitingPhase 1NCT05492682
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Studying Myxoid/round cell liposarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Valo Therapeutics Oy
- Intervention
- PeptiCRAd-1(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (3)
- Krankenhaus Nordwest, Frankfurt, Germany
- National Center for Tumor Diseases, Heidelberg, Germany
- Universitätsklinikum Tübingen, Tübingen, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05492682 on ClinicalTrials.govOther trials for Myxoid/round cell liposarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06644755First-in-Human Trial of DS-2243a in Participants With Advanced Solid TumorsDaiichi Sankyo
- RECRUITINGPHASE1NCT06414434BTX-A51 in Patients With Liposarcoma or CIC-rearranged SarcomaMichael Wagner, MD
- RECRUITINGPHASE1NCT06083883Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1M.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT04044768Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell LiposarcomaUSWM CT, LLC